SADDLE BROOK, N.J.--(BUSINESS WIRE)--Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, today announced a key executive addition to the company’s leadership team. Jeff Edelson, MD, previously employed by Johnson & Johnson (J&J) as Vice President, Internal Medicine and Therapeutic Area Head – Novel Therapeutics, has joined ITI as Executive Vice President, R&D, and Chief Medical Officer.
